Press release
Hyperphosphatemia Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Ardelyx, Shield Therapeutics, Kyowa Kirin Co., Ltd., Shanghai Alebund Pharma, Sanofi, Bayer, Keryx
DelveInsight's "Hyperphosphatemia Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Hyperphosphatemia, historical and forecasted epidemiology as well as the Hyperphosphatemia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Hyperphosphatemia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Hyperphosphatemia Market Forecast [https://www.delveinsight.com/sample-request/hyperphosphatemia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Some of the key facts of the Hyperphosphatemia Market Report:
*
The Hyperphosphatemia market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
*
In September 2024, Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company focused on kidney disease treatments, announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Oxylanthanum Carbonate (OLC). The application seeks approval for OLC as a treatment for hyperphosphatemia in patients with chronic kidney disease (CKD) undergoing dialysis. The company is pursuing FDA approval through the 505(b)(2) regulatory pathway.
*
In 2023, the United States recorded the highest prevalence of Hyperphosphatemia in the 7MM, with approximately 500,000 cases.
*
In 2023, Germany had the highest prevalence of cases among the EU4 countries and the UK, with approximately 56,000 cases.
*
Japan reported the second-highest prevalence among the 7MM in 2023, with approximately 300,000 cases.
*
According to DelveInsight's estimates, the United States had approximately 2.4 million prevalent cases of CKD stages 3-5 in 2023.
*
The United States had the largest market size for Hyperphosphatemia in the 7MM, estimated at around USD 2,400 million.
*
In 2023, Germany made the largest market size contribution among the EU4 countries and the UK, totaling approximately USD 150 million.
*
Key Hyperphosphatemia Companies: FRESENIUS MEDICAL CARE RENAL PHARMACEUTICALS, Astellas pharma, Unicycive Therapeutics, Ardelyx, Shield Therapeutics, Kyowa Kirin Co., Ltd., Shanghai Alebund Pharma, Sanofi, Bayer, Keryx Biopharma, Kissei Pharma, Taisho Pharma, Alebund Pharmaceuticals, Nabi Biopharma, Astellas Pharma Inc, Novartis, Sanofi, Mitsubishi Tanabe Pharma, and others
*
Key Hyperphosphatemia Therapies: VELPHORO/P-TAL, KIKLIN, Oxylanthanum Carbonate (OLC), Ibsrela (tenapanor), PT20, KHK7791, Tenapanor, VS-505, Sevelamer Carbonate (GZ419831), Lanthanum Carbonate (BAY77-1931), Ferric Citrate, PA21, TS-172, AP-306, calcium acetate, ASP1585, SBR759A, Renvela Registered , MCI-196, and others
*
The Hyperphosphatemia epidemiology based on gender analyzed that Hyperphosphatemia occurs in both men and women
*
The Hyperphosphatemia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Hyperphosphatemia pipeline products will significantly revolutionize the Hyperphosphatemia market dynamics.
Hyperphosphatemia Overview
A rise in serum phosphate levels exceeding 4.5 mg/100 mL indicates the presence of hyperphosphatemia. In individuals with chronic kidney disease (CKD), the illness is typically brought on by a decline in renal function, which causes phosphate levels to rise unusually high.
Get a Free sample for the Hyperphosphatemia Market Report
https://www.delveinsight.com/report-store/hyperphosphatemia-market [https://www.delveinsight.com/report-store/hyperphosphatemia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Hyperphosphatemia Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Hyperphosphatemia Epidemiology Segmentation:
The Hyperphosphatemia market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
*
Total Prevalence of Hyperphosphatemia
*
Prevalent Cases of Hyperphosphatemia by severity
*
Gender-specific Prevalence of Hyperphosphatemia
*
Diagnosed Cases of Episodic and Chronic Hyperphosphatemia
Download the report to understand which factors are driving Hyperphosphatemia epidemiology trends @ Hyperphosphatemia Epidemiology Forecast [https://www.delveinsight.com/sample-request/hyperphosphatemia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Hyperphosphatemia Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hyperphosphatemia market or expected to get launched during the study period. The analysis covers Hyperphosphatemia market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Hyperphosphatemia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Hyperphosphatemia Therapies and Key Companies
*
VELPHORO/P-TAL: FRESENIUS MEDICAL CARE RENAL PHARMACEUTICALS
*
KIKLIN: Astellas pharma
*
Oxylanthanum Carbonate (OLC): Unicycive Therapeutics
*
Ibsrela (tenapanor): Ardelyx
*
PT20: Shield Therapeutics
*
KHK7791: Kyowa Kirin Co., Ltd.
*
Tenapanor: Ardelyx
*
VS-505: Shanghai Alebund Pharma
*
Sevelamer Carbonate (GZ419831): Sanofi
*
Lanthanum Carbonate (BAY77-1931): Bayer
*
Ferric Citrate: Keryx Biopharma
*
PA21: Kissei Pharma
*
TS-172: Taisho Pharma
*
AP-306: Alebund Pharmaceuticals
*
calcium acetate: Nabi Biopharmaceuticals
*
ASP1585: Astellas Pharma Inc
*
SBR759A: Novartis
*
Renvela Registered : Sanofi
*
MCI-196: Mitsubishi Tanabe Pharma
Discover more about therapies set to grab major Hyperphosphatemia market share @ Hyperphosphatemia Treatment Market [https://www.delveinsight.com/sample-request/hyperphosphatemia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Hyperphosphatemia Market Drivers
*
Promising pipeline activity with newer mechanism of actions
*
Upsurging research and development
*
Large target population
Hyperphosphatemia Market Barriers
*
Poor knowledge of phosphate levels in food and phosphate management
*
High economic burden
*
Gastrointestinal side effects
*
High market competition
*
Lack of epidemiology data
Scope of the Hyperphosphatemia Market Report
*
Study Period: 2020-2034
*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
*
Key Hyperphosphatemia Companies: FRESENIUS MEDICAL CARE RENAL PHARMACEUTICALS, Astellas pharma, Unicycive Therapeutics, VELPHORO/P-TAL, KIKLIN, Oxylanthanum Carbonate (OLC), Ardelyx, Shield Therapeutics, Kyowa Kirin Co., Ltd., Shanghai Alebund Pharma, Sanofi, Bayer, Keryx Biopharma, Kissei Pharma, Taisho Pharma, Alebund Pharmaceuticals, Nabi Biopharma, Astellas Pharma Inc, Novartis, Sanofi, Mitsubishi Tanabe Pharma, and others
*
Key Hyperphosphatemia Therapies: VELPHORO/P-TAL, KIKLIN, Oxylanthanum Carbonate (OLC), Ibsrela (tenapanor), PT20, KHK7791, Tenapanor, VS-505, Sevelamer Carbonate (GZ419831), Lanthanum Carbonate (BAY77-1931), Ferric Citrate, PA21, TS-172, AP-306, calcium acetate, ASP1585, SBR759A, Renvela Registered , MCI-196, and others
*
Hyperphosphatemia Therapeutic Assessment: Hyperphosphatemia current marketed and Hyperphosphatemia emerging therapies
*
Hyperphosphatemia Market Dynamics: Hyperphosphatemia market drivers and Hyperphosphatemia market barriers
*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
*
Hyperphosphatemia Unmet Needs, KOL's views, Analyst's views, Hyperphosphatemia Market Access and Reimbursement
To know more about Hyperphosphatemia companies working in the treatment market, visit @ Hyperphosphatemia Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/hyperphosphatemia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Table of Contents
1. Hyperphosphatemia Market Report Introduction
2. Executive Summary for Hyperphosphatemia
3. SWOT analysis of Hyperphosphatemia
4. Hyperphosphatemia Patient Share (%) Overview at a Glance
5. Hyperphosphatemia Market Overview at a Glance
6. Hyperphosphatemia Disease Background and Overview
7. Hyperphosphatemia Epidemiology and Patient Population
8. Country-Specific Patient Population of Hyperphosphatemia
9. Hyperphosphatemia Current Treatment and Medical Practices
10. Hyperphosphatemia Unmet Needs
11. Hyperphosphatemia Emerging Therapies
12. Hyperphosphatemia Market Outlook
13. Country-Wise Hyperphosphatemia Market Analysis (2020-2034)
14. Hyperphosphatemia Market Access and Reimbursement of Therapies
15. Hyperphosphatemia Market Drivers
16. Hyperphosphatemia Market Barriers
17. Hyperphosphatemia Appendix
18. Hyperphosphatemia Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=hyperphosphatemia-market-forecasted-to-surge-in-coming-years-20242034-analysis-by-delveinsight-ardelyx-shield-therapeutics-kyowa-kirin-co-ltd-shanghai-alebund-pharma-sanofi-bayer-keryx]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Hyperphosphatemia Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Ardelyx, Shield Therapeutics, Kyowa Kirin Co., Ltd., Shanghai Alebund Pharma, Sanofi, Bayer, Keryx here
News-ID: 3781596 • Views: …
More Releases from ABNewswire
New Report Sheds Light on How Women Are Taking Control of Their Futures Through …
Global data and real-life stories reveal rising empowerment as more women make informed reproductive choices
A new report highlights a major global shift as women increasingly take control of their health, autonomy, and long-term planning through improved access to contraception. The movement reflects growing awareness, education, and empowerment across developing and developed regions alike.
According to the World Health Organization (WHO), global contraceptive use among women of reproductive age has risen from…
Industry Report Finds Employers Investing in Experiences, Not Things, to Inspire …
A growing number of organizations are rethinking traditional reward systems as they look to combat employee disengagement, turnover, and burnout. According to a recent industry analysis, companies are now prioritizing experiential incentives - offering employees memorable experiences over material perks - as a more sustainable path to motivation and retention.
A growing number of organizations are rethinking traditional reward systems as they look to combat employee disengagement, turnover, and burnout. According…
Northwestern University's Mercouri Kanatzidis Receives Prestigious Albert Einste …
MONTERREY, MEXICO - October 24, 2025 - International pride, Professor Mercouri G. Kanatzidis, from Northwestern University and Senior Scientist at Argonne National Laboratory, was honored yesterday with the 2025 Albert Einstein World Award of Science at a ceremony held in the Auditorium of the Museo de Arte Contemporaneo MARCO in Monterrey, Mexico. The award, presented by the World Cultural Council (WCC), recognizes Professor Kanatzidis's groundbreaking contributions to solar energy conversion…
Gustav Ulm Announces Relocation of Company Headquarters in Dortmund
The new headquarters opens November 1, 2025, at Am Hackenbeck 4d, 44388 Dortmund.
Image: https://www.abnewswire.com/upload/2025/10/8e48c58011e0f4fe21ca274f4d2acd49.jpg
Gustav Ulm, a trusted name in moving and relocation services since 1937, proudly announces the relocation of its company headquarters. Effective November 1, 2025, the moving company's new address will be Am Hackenbeck 4d, 44388 Dortmund, Germany [https://share.google/Zs2IUNKFJTeGdxqbv], transitioning from its previous headquarters at Im Defdahl 5 d, 44141 Dortmund [https://share.google/fZAwcWGguY0xY2VUE].
With nearly nine decades of experience, Gustav…
More Releases for Hyperphosphatemia
Hyperphosphatemia Market to Reach USD 10.3 Billion by 2034
Hyperphosphatemia is a metabolic disorder characterized by abnormally elevated phosphate levels in the blood, most often associated with chronic kidney disease (CKD) and end-stage renal disease (ESRD). When kidneys fail to excrete phosphate efficiently, it accumulates, leading to vascular calcification, bone disorders, and increased cardiovascular risk.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71967
It remains a major complication in CKD and dialysis patients, making phosphate control a critical component…
Key Trends Reshaping the Hyperphosphatemia Treatment Market: Rising Emphasis On …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Hyperphosphatemia Treatment Market Size Growth Forecast: What to Expect by 2025?
The market size for hyperphosphatemia treatment has seen a swift expansion in the recent past. The projected growth is from $4.56 billion in 2024 to $5.08 billion in 2025, reflecting a compound annual growth rate (CAGR) of 11.4%.…
Sustainable Growth Of Hyperphosphatemia Treatment Market Amid Rising Chronic Dis …
Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations.
What Will the Hyperphosphatemia Treatment Industry Market Size Be by 2025?
The market for hyperphosphatemia treatment has expanded quickly in recent years. Its size is set to increase from $4.56 billion in 2024 to $5.13 billion in 2025, with a compound annual growth rate (CAGR) of 12.4%. The extension during the historical period is…
Key Influencer in the Hyperphosphatemia Treatment Market 2025: Sustainable Growt …
What industry-specific factors are fueling the growth of the hyperphosphatemia treatment market?
The rise in chronic illnesses among patients is boosting the hyperphosphatemia treatment market. Conditions like cardiovascular and kidney diseases, chronic respiratory conditions, hyperparathyroidism, diabetes, and cancer all fall under the category of chronic diseases, which are non-communicable and demand long-term management. For instance, the World Health Organization reported in September 2023 that 74% of the 41 million global deaths…
Hyperphosphatemia Pipeline Insight Report 2024
(Albany, United States) As per DelveInsight's assessment, globally, the Hyperphosphatemia Pipeline constitutes 15+ key companies continuously working towards developing 15+ Hyperphosphatemia Pipeline treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.
In the Hyperphosphatemia Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Hyperphosphatemia NDA approvals (if any), and product development activities comprising…
Hyperphosphatemia Drugs Market to Witness Robust Expansion by 2029
The Hyperphosphatemia Drugs Market size is expected to grow at an annual average of CAGR 2% during the forecast period (2023-2029). Hyperphosphatemia is characterized by an elevated level of phosphate in the blood as a result of increased intake of phosphate, migration of phosphate out of the cells, and decreased excretion of phosphate. Hyperphosphatemia is frequently found in people who suffer from chronic kidney diseases, diabetic uncontrolled diabetes, and low…
